Why Steroid-Toxicity Must Be Measured: The Clinical and Economic Case
Patients receiving oral steroids for three to four years carry twice the risk of death compared with steroid-naive control groups. That figure comes from a 2022 population-based study of 223,211 oral ...
Three Phase 3 Trials, Three Decisions to Measure Steroid-Toxicity Directly
Patients on long-term steroids for autoimmune and inflammatory diseases know the damage that these drugs cause. The question for sponsors has long been whether a trial can prove it. In June 2026, ...
Obexelimab Reduces Disease Flares and Steroid-Toxicity in IgG4-RD
An exciting Phase 3 trial has confirmed that obexelimab significantly reduces the risk of disease flare in IgG4-related disease (IgG4-RD) while also delivering measurable reductions in ...
Steroid-Sparing Is Not Enough: GCA Trials Need Toxicity Data
New phase 3 data from the GCAptAIN trial show that secukinumab enabled a shorter steroid taper, less exposure, and meaningfully lower steroid-toxicity in giant cell arteritis (GCA). Although the ...
Secukinumab Delivers Sustained Remission and Toxicity Reduction in PMR
For the majority of patients with polymyalgia rheumatica, glucocorticoids do not provide a durable solution. They induce remission, but they do not maintain it. REPLENISH, the largest PMR clinical ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
